Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study.
E M H SchmitzP J BoekemaJ W A StraathofD C van RenswouwL BrunsveldV ScharnhorstM E C van de PollM A C BroerenL J J DerijksPublished in: Alimentary pharmacology & therapeutics (2017)
We found no differences in drug levels and disease activity between infliximab innovator and biosimilar in our IBD cohort, indicating that biosimilars are safe and effective. The high proportions of discontinuers were mostly due to elective withdrawal or subjective disease worsening.
Keyphrases
- disease activity
- patients with inflammatory bowel disease
- ulcerative colitis
- systemic lupus erythematosus
- rheumatoid arthritis
- rheumatoid arthritis patients
- ankylosing spondylitis
- juvenile idiopathic arthritis
- cross sectional
- patients undergoing
- clinical trial
- study protocol
- double blind
- adverse drug
- emergency department
- randomized controlled trial
- drug induced
- physical activity